Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
May 18, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
May 15, 2026 09:45 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic Dermatitis

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
May 04, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
March 16, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments

– Ajay Nirula, M.D., Ph.D., will now also serve as president, in addition to his role as head of research and development - Catherine Bovenizer, C.P.A., has been named chief financial officer,...
January 12, 2026 08:05 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors

Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of $123 million in equity financing received from...
January 12, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025 --In preclinical studies, REX-8756 elicited complete, rapid and...
January 08, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
January 07, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
December 16, 2025 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces FDA Clearance of Investigational New Drug Application for REX-8756, an Oral STAT6 Inhibitor, to Enter into the Clinic

REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and...